Fact Source: Financial Supervisory Service DART / 2025-06-10
Disclosure Type: Execution of a Single Sales/Supply Contract (Voluntary Disclosure)
💡 3-Second Summary
Samsung Biologics has signed a pharmaceutical contract manufacturing organization (CMO) agreement worth approximately KRW 102.5 billion with a European-based pharmaceutical firm, which accounts for 2.25% of its annual revenue.
📊 1. [Key Disclosure Content & Summary of Financial Figures]
- Company Name: Samsung Biologics Co., Ltd. (207940)
- Contract Name: Contract Manufacturing Agreement for Pharmaceuticals
- Contract Amount: KRW 102,450,596,470 (Calculated based on the fixed contract amount of USD 75,392,300, applying the initial standard proxy rate of USD/KRW 1,358.90 as of June 10, 2025)
- Ratio to Recent Sales: 2.25% (Recent annual sales: KRW 4,547,322,176,421 based on the 2024 consolidated financial statements)
- Counterparty: A pharmaceutical company located in Europe (Identity deferred due to business confidentiality until December 31, 2031)
- Contract Period: June 10, 2025 – December 31, 2031
- Key Terms & Conditions:
- No contract deposit or advance payment (None).
- The contract end date, contract amount, and the disclosure deferral expiration date are subject to change upon mutual agreement.
📈 2. [Expert Insight: What This Disclosure Means for Investors]
This announcement pertains to the execution of a commercial supply contract filed as a voluntary disclosure, highlighting an order where the fixed Korean Won value represents approximately 2.25% of the company’s recent annual consolidated revenue. Investors can assess the company’s long-term order backlog by verifying the specified contract period running from June 10, 2025, to December 31, 2031.
The specific identity of the counterparty remains undisclosed until December 31, 2031, for reasons of business confidentiality, and this target date may shift in the future. The contract amount stated in the disclosure is anchored to the fixed USD value (USD 75,392,300), which was converted using the initial standard proxy rate (USD/KRW 1,358.90) on the date of the contract. Additionally, since the disclosure explicitly indicates that there is no contract deposit or advance payment, investors may track the progress of the schedule by referencing the formal terms provided in the filing.
📝 Editor’s Comment (by K-STOCK Editor)
Samsung Biologics has disclosed a contract manufacturing agreement worth approximately KRW 102.5 billion with a European pharmaceutical company. The core fact is that the company secured a fixed contract amount representing 2.25% of its recent annual sales. The client’s detailed information remains confidential until the end of 2031, and the stated figures are based on the foreign currency value calculated using the standard exchange rate on June 10. Given the contract conditions, including the absence of upfront advance payments, investors are advised to review the specified timeline and conditions as reported in the official disclosure.
📢 Disclaimer & Source Information
Source: This content has been structured and newly generated based on the official data submitted to the Financial Supervisory Service electronic disclosure system (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
